The global protein therapeutics market grew at a CAGR of around 7% during 2014-2019. Protein therapeutics refers to artificially synthesized protein-based medicines. They are fast-acting, potent medicines that deliver small protein molecules to the body in a specific amount. They usually consist of recombinant forms of naturally occurring proteins, such as monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormones (HGH) and follicle-stimulating hormones. They aid in treating chronic medical ailments, such as cancer, diabetes, neurodegenerative disorders and immunological, hematological, hormonal and genetic disorders. Various combination therapy drugs are also used with protein therapeutics that can be inhaled, injected or orally administered.
Global Protein Therapeutics Market Growth Drivers:
The increasing prevalence of chronic medical ailments is one of the key factors driving the growth of the protein therapeutics market. In line with this, the rising awareness among the masses regarding the benefits of protein therapeutics, such as minimal risks of side effects and high efficiency, are contributing to the market growth. Monoclonal antibodies are being widely researched and used for the treatment of various viral and bacterial diseases and pharmaceutical companies are using protein therapeutics for drug discovery and development. The sudden outbreak of the coronavirus disease (COVID-19) is further providing growth opportunities to market players. For instance, Molecular Partners AG, a Switzerland-based clinical stage biotechnology company, is developing a new class of protein therapeutics, called DARPin®, to inhibit the proliferation of the virus.
The development of novel recombinant proteins, peptides, antibody-based drugs and plasma proteins is acting as other-growth inducing factors. These protein therapeutics are extensively used in replacement therapies to treat genetic and autoimmune disorders, such as dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Other factors, including extensive research and development (R&D) activities in the field of protein engineering, along with significant improvements in the healthcare infrastructure, are expected to drive the market further. Looking forward, IMARC Group expects the global protein therapeutics market to continue its moderate growth during the next five years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global protein therapeutics market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, product, therapy area and function.
Breakup by Product:
Breakup by Therapy Area:
Breakup by Function:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Abbott Laboratories, Abbvie Inc., Baxter International Inc., Biogen Inc., Csl Behring L.L.C. (CSL Limited), Eli Lilly and Company, F. Hoffmann-La Roche AG (Roche Holding AG), Johnson & Johnson, Merck & Co. Inc., Novo Nordisk A/S (Novo Holdings A/S) and Pfizer Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at